These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Thyroid cancer: successful remnant ablation-what is success? Links TP; van der Horst-Schrivers AN Nat Rev Endocrinol; 2012 Sep; 8(9):514-5. PubMed ID: 22751340 [No Abstract] [Full Text] [Related]
7. Well-being after radiation therapy in thyroid cancer. Hackshaw A; Kadalayil L; Mallick U N Engl J Med; 2013 Feb; 368(7):685-6. PubMed ID: 23406048 [No Abstract] [Full Text] [Related]
8. [Current trends in treatment and follow-up of patients with differentiated thyroid carcinoma - experience with the use of recombinant human thyrotropin]. Macková M; Vlček P Vnitr Lek; 2013 Feb; 59(2):106-12. PubMed ID: 23461399 [TBL] [Abstract][Full Text] [Related]
9. High-risk patients with differentiated thyroid cancer T4 primary tumors achieve remnant ablation equally well using rhTSH or thyroid hormone withdrawal. Bartenstein P; Calabuig EC; Maini CL; Mazzarotto R; Muros de Fuentes MA; Petrich T; Rodrigues FJ; Vallejo Casas JA; Vianello F; Basso M; Balaguer MG; Haug A; Monari F; Vaňó RS; Sciuto R; Magner J Thyroid; 2014 Mar; 24(3):480-7. PubMed ID: 24040896 [TBL] [Abstract][Full Text] [Related]
10. Radioiodine therapy of metastatic lesions of differentiated thyroid cancer. Luster M; Hänscheid H; Freudenberg LS; Verburg FA J Endocrinol Invest; 2012; 35(6 Suppl):21-9. PubMed ID: 23014070 [TBL] [Abstract][Full Text] [Related]
11. Absence of bone marrow toxicity in elderly patients treated with recombinant human thyroid-stimulating hormone and empirically dosed radioiodine for thyroid cancer. Amdur RJ; Dan T; Mazzaferri E Am J Clin Oncol; 2013 Aug; 36(4):348-53. PubMed ID: 22547013 [TBL] [Abstract][Full Text] [Related]
12. Sialadenitis following low dose I-131 diagnostic thyroid scan with Thyrogen® (recombinant human thyroid stimulating hormone--thyrotropin alfa). Gonzalez ME; Muttikkal TJ; Rehm PK J Radiol Case Rep; 2015 Jun; 9(6):44-9. PubMed ID: 26622936 [TBL] [Abstract][Full Text] [Related]
13. Postoperative use of radioiodine (131-I): review of recommendations and guidelines. Prpić M; Jukić T; Murgić J; Borić M; Stanicić J; Kusić Z Coll Antropol; 2011 Jun; 35(2):587-94. PubMed ID: 21755735 [TBL] [Abstract][Full Text] [Related]
14. Recombinant human thyroid-stimulating hormone in radioiodine thyroid remnant ablation. Mylonas C; Zwas ST; Rotenberg G; Omry G; Cohen O Isr Med Assoc J; 2014 Feb; 16(2):106-9. PubMed ID: 24645230 [TBL] [Abstract][Full Text] [Related]
15. Recombinant human thyroid stimulating hormone in thyroid remnant ablation with 1.1 GBq 131iodine in low-risk patients. Rosario PW; Xavier AC Am J Clin Oncol; 2012 Apr; 35(2):101-4. PubMed ID: 21297429 [TBL] [Abstract][Full Text] [Related]
16. Radioiodine post-surgical remnant ablation in patients with differentiated thyroid cancer: news from the last 10 years. Molinaro E; Pieruzzi L; Viola D J Endocrinol Invest; 2012; 35(6 Suppl):16-20. PubMed ID: 23014069 [TBL] [Abstract][Full Text] [Related]
17. The HiLo trial: a multicentre randomised trial of high- versus low-dose radioiodine, with or without recombinant human thyroid stimulating hormone, for remnant ablation after surgery for differentiated thyroid cancer. Mallick U; Harmer C; Hackshaw A Clin Oncol (R Coll Radiol); 2008 Jun; 20(5):325-6. PubMed ID: 18474322 [No Abstract] [Full Text] [Related]
18. Recombinant human thyroid-stimulating hormone as an alternative for thyroid hormone withdrawal in thyroid cancer management. Chen MK; Doddamane I; Cheng DW Curr Opin Oncol; 2010 Jan; 22(1):6-10. PubMed ID: 19844179 [TBL] [Abstract][Full Text] [Related]
19. Long-term follow-up of at least five years after recombinant human thyrotropin compared to levothyroxine withdrawal for thyroid remnant ablation with radioactive iodine. Rosario PW; Mineiro Filho AF; Lacerda RX; Calsolari MR Thyroid; 2012 Mar; 22(3):332-3. PubMed ID: 22233130 [No Abstract] [Full Text] [Related]
20. [Radiometabolic therapy for metastatic thyroid carcinoma: overview of the literature and rational bases for the use of recombinant human TSH]. Testori O; Bagnasco M; Banti E; Bombardieri E; Dottorini ME; Fugazzola L; Maffioli L; Perotti G; Rubello D; Seregni E Minerva Med; 2012 Jun; 103(3):209-18. PubMed ID: 22653101 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]